Today's edition · Wednesday, November 18, 2026
Every story verifiedNo politics. Ever.No pop-ups
TodayLocalWorldHeroesAnimalsScienceCommunityHealth & TechMapQuizKindnessAnnouncementsKidsTopicsExplainersOn this dayCalendarGood NeighborHometown Heroes

TodayHealth & TechMaryland

Health & TechSilver Spring, Maryland

FDA approves Roche's oral pill giredestrant for advanced breast cancer

The FDA approved giredestrant with everolimus for a specific advanced breast cancer. In a 207-patient trial it cut the risk of progression or death by 62%.

Verified · Source: ReutersNov 16, 2026 · 1 min read
How to help
The curved glass and metal exterior of an FDA office building
Photo of an FDA building in the agency's campus. It does not show the pill, a patient, or a clinic. U.S. Food and Drug Administration / Wikimedia Commons · Public domain

Read the original

The reporting lives at Reuters. Our summary is checked against it, and we link it on every story.

The FDA approved Roche's oral pill giredestrant, given with everolimus, for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after hormone therapy, Reuters reported. In a late-stage trial of 207 patients, the combination cut the risk of progression or death by 62 percent. The median time without progression was 10 months, compared with 5.5 months without the combination.

The approval is for that specific advanced cancer after hormone therapy. The 207 patients are the trial group behind the 62 percent figure. This is an approval of a treatment studied in that trial, not a claim that every case follows the same course.

More good news

Other stories in the same neighborhood of kindness.

A row of glass laboratory beakers on a white surfaceHealth & Tech
Silver Spring, Maryland

The FDA approved a pre-surgery bladder cancer combo

The FDA approved durvalumab, sold as Imfinzi, plus enfortumab vedotin before bladder removal, then durvalumab afterward, for muscle-invasive bladder cancer in patients who cannot take cisplatin or who decline it. In the 695-patient VOLGA trial the combo cut the risk of an event by about half. It is not a cure.

Verified · U.S. Food and Drug Administration
A scientist in a white coat working with sample tubes at a laboratory benchHealth & Tech
Silver Spring, Maryland

The FDA approved the first drug for a rare kidney disease

The FDA approved Gazyva, obinutuzumab, for adults with primary membranous nephropathy at risk of getting worse, to induce remission of protein in the urine. In a 142-person trial, 36 percent reached complete remission at week 104, compared with 6 percent on tacrolimus. It is not a cure.

Verified · U.S. Food and Drug Administration